CARA vs. ALEC, TNXP, SLN, COYA, BHST, IMUX, ELUT, ZURA, GNLX, and OPTN
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Alector (ALEC), Tonix Pharmaceuticals (TNXP), Silence Therapeutics (SLN), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), Immunic (IMUX), Elutia (ELUT), Zura Bio (ZURA), Genelux (GNLX), and OptiNose (OPTN). These companies are all part of the "pharmaceutical products" industry.
Cara Therapeutics vs.
Alector (NASDAQ:ALEC) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
Alector has a net margin of -257.54% compared to Cara Therapeutics' net margin of -1,099.76%. Alector's return on equity of -108.77% beat Cara Therapeutics' return on equity.
Alector presently has a consensus target price of $3.50, suggesting a potential upside of 196.61%. Cara Therapeutics has a consensus target price of $83.52, suggesting a potential upside of 0.00%. Given Alector's stronger consensus rating and higher probable upside, research analysts plainly believe Alector is more favorable than Cara Therapeutics.
85.8% of Alector shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 9.1% of Alector shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cara Therapeutics has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alector had 1 more articles in the media than Cara Therapeutics. MarketBeat recorded 2 mentions for Alector and 1 mentions for Cara Therapeutics. Alector's average media sentiment score of 1.08 beat Cara Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media.
Cara Therapeutics received 511 more outperform votes than Alector when rated by MarketBeat users. Likewise, 72.11% of users gave Cara Therapeutics an outperform vote while only 60.94% of users gave Alector an outperform vote.
Alector has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Summary
Alector beats Cara Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CARA) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy CARA Stock Free CARA Stock Alerts